Details for Patent: 7,465,465

Which drugs does patent 7,465,465 protect, and when does it expire?

Patent 7,465,465 protects FOSRENOL and is included in two NDAs.

This patent has seventy-six patent family members in thirty-one countries.

Summary for Patent: 7,465,465

Title:	Pharmaceutical formulation comprising lanthanum compounds
Abstract:	This invention relates to a chewable lanthanum formulation comprising a pharmaceutically effective amount of a lanthanum compound; and at least one chewable pharmaceutically acceptable excipient. This invention also relates to a pharmaceutical formulation in a tablet or in a powder comprising a pharmaceutically effective amount of a lanthanum compound produced by a process which comprises the steps of: a) powder blending the lanthanum compound and at least one pharmaceutically acceptable excipient in a mixer to form a mixture; or b) powder blending the lanthanum compound and excipients, compressing the resulting combination into a slug material or roller compacting the resulting combination into a strand material, and milling the prepared material into a free flowing mixture; and c) compressing the resulting mixture into a tablet or filing up the resulting mixture in a appropriate container.
Inventor(s):	Haslam; Robert Paul (Pewsey, GB), Trespidi; Laura Anna (Pizzighettone, IT), Ferdinando; Josephine Christine (Tadley, GB)
Assignee:	Shire Biochem Inc. (Laval, Quebec, CA)
Application Number:	10/926,330
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,465,465
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Dosage form; Process; Use;

Drugs Protected by US Patent 7,465,465

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Takeda Pharms Usa	FOSRENOL	lanthanum carbonate	POWDER;ORAL	204734-002	Sep 24, 2014		RX	Yes	Yes			Y
Takeda Pharms Usa	FOSRENOL	lanthanum carbonate	POWDER;ORAL	204734-001	Sep 24, 2014		RX	Yes	No			Y
Takeda Pharms Usa	FOSRENOL	lanthanum carbonate	TABLET, CHEWABLE;ORAL	021468-004	Nov 23, 2005	AB	RX	Yes	Yes			Y
Takeda Pharms Usa	FOSRENOL	lanthanum carbonate	TABLET, CHEWABLE;ORAL	021468-001	Oct 26, 2004		DISCN	No	No			Y
Takeda Pharms Usa	FOSRENOL	lanthanum carbonate	TABLET, CHEWABLE;ORAL	021468-002	Oct 26, 2004	AB	RX	Yes	No			Y

International Family Members for US Patent 7,465,465

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	056609
Austria	460169
Austria	9809
Australia	2004266050
Australia	2006313490